| http://www.w3.org/ns/prov#value | - ing sufficient quantities of clinical trial material, being subject to a clinical hold, and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of a planned clinical study of a pr
|
